Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

To assess the influence of seasonal variations in Schistosoma haematobium transmission on treatment outcome (morbidity and re-infection)

Condition or disease	Intervention/treatment	Phase
Hematuria; Hydronephrosis	Drug: praziquantel	Not Applicable

Detailed Description:

General objective To provide knowledge about the influence of transmission season (high and low) on the outcome of treatment assessed by cure rate, re-infection rate, regression and reappearance of urinary tract morbidity rate after treatment in order to optimise praziquantel treatment strategies for morbidity control in urinary schistosomiasis.

Specific objectives To determine the prevalence and intensity of Schistosoma haematobium infection before chemotherapy and compare cure rates and levels of re-infection after chemotherapy administered during high and low transmission seasons.

To assess urinary tract morbidity due to Schistosoma haematobium by ultrasonography and compare the regression and reappearance of urinary tract pathology chemotherapy administered during high and low transmission seasons.

To correlate morbidity determined by ultrasound with infection and morbidity parameters such as intensity of infection, micro- and macrohematuria, circulating cathodic antigen (CCA) in urine, proteinuria and leucocyturia and determine sensitivity, specificity and positive predictive values in relation to urinary tract morbidity.

Study design The main research question concerning the influence of transmission season on treatment outcome will be addressed in a consecutive cohort study with two separate but comparable cohorts. The first cohort will be examined and treated with praziquantel during the season with high transmission, February/Mach (group A) and the second cohort will be examined and treated during the low transmission season, in July approximately 5 months later (group B). Each cohort will be examined before treatment and 2, 6 and 18 months after treatment.

The study will be carried out in 4 primary schools; two from Machava J area and two from Costa do Sol area. The schools will be selected based on the following criteria: similar prevalence (> 50%) and intensity of S. haematobium infection; absence or very low levels of S. mansoni infection; a minimum of 2 classes (>35 pupils per class) at each level (3rd and 4th level) and similar distribution of boys and girls.Examinations will include urine for parasitology and haematuria and ultrasonography of upper and lower urinary tract

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Enrollment :	520 participants
Allocation:	Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique
Study Start Date :	March 2004
Study Completion Date :	March 2006

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. cure rate
2. egg reduction rate
3. re-infection prevalence and intensity of infection *resolution of urinary tract pathology
4. re-appearance of pathology after re-infection.

Secondary Outcome Measures :

1. reduction in worm burden (CAA);

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	8 Years to 12 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• children aged 8-12 years

Exclusion Criteria:

• All children presenting with macro-haematuria or severe pathology detected by ultrasonography (large masses, pseudo-polyps or hydronephrosis/hydroureter) at the 6 months follow-up examination will be treated with praziquantel and excluded in the data analysis.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Mozambique
Matola
Maputo, Maputo Province, Mozambique

Sponsors and Collaborators

DBL -Institute for Health Research and Development

Durban University of Technology South Africa

Investigators

Principal Investigator:	Gerito Augusto, Msc	Instituto Nacional de Saúde

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

Related Info 

ClinicalTrials.gov Identifier:	NCT00231322 History of Changes
Other Study ID Numbers:	30/CNSB/03/624-03-0021
First Posted:	October 4, 2005
Last Update Posted:	April 20, 2007
Last Verified:	April 2007

Keywords provided by DBL -Institute for Health Research and Development:

Schistosoma haematobium; haematuria; ultrasonography; Uganda; Vesical polyps

Additional relevant MeSH terms:

Hydronephrosis; Hematuria; Schistosomiasis haematobia; Kidney Diseases; Urologic Diseases; Urination Disorders; Hemorrhage; Pathologic Processes; Urinary Tract Infections	Infection; Schistosomiasis; Trematode Infections; Helminthiasis; Parasitic Diseases; Praziquantel; Anthelmintics; Antiparasitic Agents; Anti-Infective Agents